Jennison Associates LLC Takes Position in Stevanato Group S.p.A. (NYSE:STVN)

Jennison Associates LLC purchased a new stake in shares of Stevanato Group S.p.A. (NYSE:STVN - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 928,826 shares of the company's stock, valued at approximately $20,239,000. Jennison Associates LLC owned 0.31% of Stevanato Group as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new stake in shares of Stevanato Group in the third quarter valued at $84,000. Hardy Reed LLC increased its holdings in shares of Stevanato Group by 8.2% in the 3rd quarter. Hardy Reed LLC now owns 11,077 shares of the company's stock valued at $222,000 after purchasing an additional 840 shares in the last quarter. Lindenwold Advisors INC lifted its holdings in shares of Stevanato Group by 13.5% in the third quarter. Lindenwold Advisors INC now owns 11,930 shares of the company's stock valued at $239,000 after purchasing an additional 1,415 shares in the last quarter. Raymond James Trust N.A. raised its position in shares of Stevanato Group by 22.6% in the third quarter. Raymond James Trust N.A. now owns 12,556 shares of the company's stock valued at $251,000 after buying an additional 2,317 shares during the last quarter. Finally, Captrust Financial Advisors lifted its holdings in shares of Stevanato Group by 12.7% during the 3rd quarter. Captrust Financial Advisors now owns 13,100 shares of the company's stock worth $262,000 after acquiring an additional 1,480 shares during the period.

Stevanato Group Price Performance

NYSE STVN traded up €0.54 ($0.56) on Thursday, hitting €22.47 ($23.41). 137,411 shares of the company were exchanged, compared to its average volume of 342,271. The company has a current ratio of 1.81, a quick ratio of 1.21 and a debt-to-equity ratio of 0.22. The firm has a 50 day moving average of €21.85 and a two-hundred day moving average of €20.52. Stevanato Group S.p.A. has a 1-year low of €16.56 ($17.25) and a 1-year high of €34.73 ($36.18). The company has a market cap of $6.80 billion, a P/E ratio of 47.81, a P/E/G ratio of 7.76 and a beta of 0.56.

Stevanato Group (NYSE:STVN - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported €0.12 ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of €0.13 ($0.14) by (€0.01) (($0.01)). The business had revenue of €277.90 million during the quarter, compared to the consensus estimate of €274.36 million. Stevanato Group had a return on equity of 9.86% and a net margin of 10.47%. The firm's revenue was up 2.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.16 earnings per share. On average, equities analysts predict that Stevanato Group S.p.A. will post 0.5 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently commented on STVN. Morgan Stanley reissued an "equal weight" rating and set a $23.00 price target (down from $24.00) on shares of Stevanato Group in a research report on Tuesday, December 3rd. Bank of America boosted their price target on shares of Stevanato Group from $24.00 to $26.00 and gave the stock a "buy" rating in a research report on Friday, December 13th. Finally, Wolfe Research initiated coverage on Stevanato Group in a report on Friday, December 13th. They set an "outperform" rating and a $28.00 price objective on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.com, Stevanato Group presently has a consensus rating of "Moderate Buy" and a consensus target price of €28.60 ($29.79).

About Stevanato Group

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.